Canopy Growth rally continues with 28% gain after recent talk about federal cannabis reforms
By Steve Gelsi
Stock has been rising sharply since March 14 and has gained 140% in the past week
Canopy Growth Corp.'s stock continued its rally on Wednesday with a fresh rise of 28% on heavier-than-usual volume.
The stock (CGC) (CA:WEED) has been rising in every trading session since March 14, including a gain of $2.12, to $17.39 a share, in recent action. It's the highest price level the stock has seen since September.
Volume on Wednesday topped 40 million shares, well over the average daily total of about 6 million shares.
Canopy Growth has not issued any material company announcements in recent days.
But its stock has been rising on the heels of comments this month from the Biden administration on potential reclassification of cannabis under federal law to Schedule III from its current designation as a Schedule I controlled substance.
Canopy Growth holds options to buy three U.S. cannabis companies -Acreage, Wanna Brands and Jetty Extracts - to form a business unit called Canopy USA.
Canopy Growth will hold a shareholder vote on April 12 to authorize the issuance of a new class of nonvoting and nonparticipating exchangeable shares as part of its move to create Canopy USA.
Canopy Growth also has a presence in Europe, where Germany recently decriminalized cannabis.
Also read: Canopy Growth's stock doubles to record weekly gain after Germany votes to legalize pot
Canopy Growth and other marijuana stocks have been in rally mode for much of the month of March, after President Joe Biden mentioned the rescheduling of cannabis in his State of the Union speech on March 7.
Also read: Cannabis stocks extend gains after Biden White House shows support for marijuana reforms
That was followed up by comments on March 15 by Vice President Kamala Harris, who called the current Schedule I classification for cannabis "absurd" and said that it should be rescheduled "as soon as possible."
Also read: Canadian cannabis giant Canopy Growth seeks shareholder approval to speed up entry into U.S. market
-Steve Gelsi
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
03-27-24 1516ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening in the Markets This Week
-
4 Top Dividend-Paying REIT Stock Picks
-
After Earnings, Is Netflix Stock a Buy, a Sell, or Fairly Valued?
-
P-CAPE: A Better Way for Investors to Estimate Future Returns
-
Which Stocks Have Driven the Stealth Large-Value Rally?
-
Forecasts for Q2 GDP Report Show a Healthy but Slowing Economy
-
5 Stocks to Buy as the Market Rally Broadens
-
4 Top US Travel Stock Picks
-
How Do Interest Rates Affect Stock Market Returns?
-
American Airlines Earnings: Ticket Distribution Misstep Affected Results
-
Going Into Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
3 Top Cybersecurity Stock Picks for Long-Term Investors
-
AbbVie Earnings: Firm Sees Strong Next-Generation Immunology Drugs Sales
-
Ford Earnings: Warranty Problems on Older Vehicles Slam Results
-
ServiceNow Earnings: Operating on a Higher Plane Within Enterprise Software